SCHEMBL22327282

SCHEMBL22327282

CSS[C@H](C)OC1C[C@H](n2cnc3c(=O)[nH]c(/N=C\N(C)C)nc32)O[C@@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.35
▸ TYMP P19971 1/20 0.34
▸ IMPDH2 P12268 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ POLA1 P09884 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22327279 1.00 KDM4E (0.35) KDM4ETYMPIMPDH2POLBPOLA1
SCHEMBL26068482 0.89 KDM4E (0.35) KDM4ETYMPIMPDH2POLBPOLA1
SCHEMBL26068428 0.86 TYMP (0.30) TYMP
SCHEMBL22598552 0.86 TYMP (0.30) TYMP
SCHEMBL22598550 0.86 TYMP (0.30) TYMP
SCHEMBL26068427 0.86 TYMP (0.30) TYMP
SCHEMBL24973038 0.86 PDE9A (0.31) —
SCHEMBL24973033 0.86 PDE9A (0.31) —
SCHEMBL25754150 0.86 PDE9A (0.31) —
SCHEMBL25754147 0.86 PDE9A (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257414-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-17 — — US disclosed
US-20230257414-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-17 — — US disclosed
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF LG ELECTRONICS INC. (KR) 2022-04-28 — — US disclosed
US-10822653-B1 Nucleotide cleavable linkers and uses thereof Singular Genomics Systems, Inc. (US) 2020-11-03 — — US disclosed
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2020-10-29 — — US disclosed
US-10738072-B1 Nucleotide analogues Singular Genomics Systems, Inc. (US) 2020-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A KDM4E 3403/4885TYMP 17/4885IMPDH2 446/4885
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A KDM4E 3403/4885TYMP 17/4885IMPDH2 446/4885
US-20230257414-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 KDM4E 4194/4885TYMP 5/4885IMPDH2 27/4885
US-10822653-B1 Nucleotide cleavable linkers and uses thereof NUDT21, CPSF7, DCLRE1A KDM4E 3403/4885TYMP 17/4885IMPDH2 446/4885
US-10738072-B1 Nucleotide analogues NUDT1, POLN, TYMP KDM4E 3976/4885TYMP 3/4885IMPDH2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback